Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 5/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | MEP1B | Q16820 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL320799 | 1.00 | F2 (0.39) | F2PRSS1SLC7A5MEN1KMT2A | |
| SCHEMBL12505590 | 0.78 | MEN1 (0.54) | MEN1KMT2AGAA | |
| SCHEMBL12505591 | 0.78 | MEN1 (0.54) | MEN1KMT2AGAA | |
| SCHEMBL12505623 | 0.78 | MEN1 (0.54) | MEN1KMT2AGAA | |
| SCHEMBL320483 | 0.77 | FOLH1 (0.48) | MEN1KMT2AMEP1BFOLH1 | |
| SCHEMBL2771476 | 0.76 | CD274 (0.42) | F2PRSS1MEN1KMT2AF10 | |
| SCHEMBL2771473 | 0.76 | CD274 (0.42) | F2PRSS1MEN1KMT2AF10 | |
| SCHEMBL408720 | 0.75 | SLC7A5 (0.42) | SLC7A5ALDH1A1L3MBTL1FOLH1 | |
| SCHEMBL408721 | 0.75 | SLC7A5 (0.42) | SLC7A5ALDH1A1L3MBTL1FOLH1 | |
| SCHEMBL2773039 | 0.74 | KDM4A (0.43) | F2PRSS1MEN1KMT2AMEP1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802704-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2014-08-12 | — | — | US | disclosed |
| US-20120035226-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2012-02-09 | — | — | US | disclosed |
| EP-2414341-A2 | OXADIAZOLE DERIVATIVES | Merck Serono SA (CH) | 2012-02-08 | — | — | EP | disclosed |
| EP-2414342-A1 | OXADIAZOLE DERIVATIVES | Merck Serono S.A. (CH) | 2012-02-08 | — | — | EP | disclosed |
| US-20120022109-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022109-A1 | OXADIAZOLE DERIVATIVES | OXA1L, HLA-DRB1, SSB | F2 2321/4885PRSS1 4700/4885SLC7A5 2990/4885 |
| US-20120035226-A1 | OXADIAZOLE DERIVATIVES | OXA1L, HLA-DRB1, SSB | F2 2321/4885PRSS1 4700/4885SLC7A5 2990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.